Immediate Impact
2 from Science/Nature 59 standout
Citing Papers
The present and future of bispecific antibodies for cancer therapy
2024 Standout
The hallmarks of cancer immune evasion
2024 Standout
Works of Amber C. King being referenced
Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia
2019
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Amber C. King | 116 | 104 | 200 | 156 | 31 | 411 | |
| Antonio Spadano | 92 | 59 | 273 | 178 | 31 | 391 | |
| Barbara Spitzer | 62 | 44 | 253 | 262 | 39 | 447 | |
| Sylvia F. Pan | 40 | 49 | 155 | 134 | 18 | 414 | |
| Yali Ding | 64 | 130 | 130 | 225 | 30 | 397 | |
| Sparkes Rs | 29 | 36 | 121 | 140 | 30 | 377 | |
| Taub Rn | 63 | 44 | 76 | 171 | 42 | 450 | |
| W. G. Hughes | 26 | 72 | 153 | 113 | 33 | 434 | |
| Tomoo Osumi | 100 | 53 | 85 | 108 | 54 | 359 | |
| Elena Gaber | 54 | 14 | 65 | 194 | 22 | 446 | |
| Fliedner Tm | 97 | 49 | 147 | 127 | 41 | 445 |
All Works
Login with ORCID to disown or claim papers
Loading papers...